Physician specialty
Hematology
At a glance
- Practicing in the U.S.
- 1,909
- Per 100,000 residents
- 0.6
- Women
- 40%
- Median years since graduating
- 22
Training path
- College (bachelor’s degree) 4 years
- Medical school (MD or DO) 4 years
- Internal medicine residency 3 years
- Hematology fellowship 2 years
Training after medical school: 5 years. From the start of college: about 13 years.
Usual minimum program lengths from ACGME program requirements. Some doctors take extra research years or a second fellowship.
Who they are
- MD (DOs make up the rest) 98%
- Women 40%
- Graduated 35 or more years ago 21%
- Offer telehealth 54%
- Accept Medicare’s approved amount 97%
Sex and credentials from NPPES. Graduation year, telehealth and Medicare assignment from Medicare Care Compare, which covers clinicians enrolled in Medicare.
Where they practice
What they do most for Medicare patients
- Established patient office or other outpatient visit, 30-39 minutes 131,318
- Flow cytometry technique for dna or cell analysis, each additional marker 85,667
- Established patient office or other outpatient visit, 40-54 minutes 81,888
- Detection test by nucleic acid for organism, amplified probe technique 81,879
- Special stained specimen slides to examine tissue, each additional procedure 80,329
- Pathology examination of tissue using a microscope, intermediate complexity 65,392
- Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes 63,638
- Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count 59,179
- Insertion of needle into vein for collection of blood sample 39,366
- Blood test, comprehensive group of blood chemicals 38,174
- Established patient office or other outpatient visit, 20-29 minutes 35,364
- Detection test for candida species (yeast), amplified probe technique 32,718
Services billed to traditional Medicare in 2023 (Physician and Other Practitioners data); drugs given in the office are left out.
What they prescribe most
- Acyclovir (Zovirax) 7.6%
- Apixaban (Eliquis) 6.4%
- Lenalidomide (Revlimid) 4.8%
- Hydroxyurea (Siklos, Droxia, Hydrea) 4.1%
- Prednisone (Rayos) 3.1%
- Anastrozole (Arimidex) 3.0%
- Dexamethasone (Hemady, Maxidex, Ozurdex) 2.7%
- Rivaroxaban (Xarelto) 2.5%
- Oxycodone Hcl (Oxycontin, Roxicodone, Roxybond) 2.5%
- Sulfamethoxazole/Trimethoprim (Bactrim Ds, Sulfamethoxazole-Trimethoprim) 2.4%
- Ruxolitinib Phosphate (Jakafi, Opzelura) 2.4%
- Ondansetron Hcl 2.0%
- Prochlorperazine Maleate 1.8%
- Gabapentin (Gralise, Neurontin) 1.8%
- Warfarin Sodium (Jantoven) 1.7%
Share of this specialty’s Medicare Part D prescriptions in 2024, including refills. Select a drug to see which of these clinicians prescribe it most, and where.
Hospitals where the most work
- Mayo Clinic Hospital Rochester Rochester, MN 77 Hematology at Mayo Clinic Hospital Rochester
- Brigham and Women's Hospital Boston, MA 54 Hematology at Brigham and Women's Hospital
- Ohio State University State Health System Columbus, OH 53 Hematology at Ohio State University State Health System
- Stanford Health Care Stanford, CA 42 Hematology at Stanford Health Care
- Massachusetts General Hospital Boston, MA 37 Hematology at Massachusetts General Hospital
- Carolinas Medical Center/behav Health Charlotte, NC 34 Hematology at Carolinas Medical Center/behav Health
- University of Michigan Health System Ann Arbor, MI 25 Hematology at University of Michigan Health System
- University of Utah Hospital and Clinics Salt Lake City, UT 24 Hematology at University of Utah Hospital and Clinics
- Emory University Hospital Atlanta, GA 20 Hematology at Emory University Hospital
- NYU Langone Hospitals New York, NY 20 Hematology at NYU Langone Hospitals
Clinicians who list the hospital in Medicare Care Compare. The number opens the list of who works there.
Schools they graduated from most
- Harvard Medical School 25
- Ohio State University College of Medicine 15
- Albert Einstein College of Medicine of Yeshiva University 13
- Stanford University School of Medicine 13
- Indiana University School of Medicine 11
- University of Minnesota Medical School 11
- Tufts University School of Medicine 10
- University of Michigan Medical School 10
- Baylor College of Medicine 9
- Perelman School of Med at The University of Pennsylvania 9
From Medicare Care Compare (Medicare-enrolled clinicians only).
Industry payments
Drug and device makers reported $9.6M in general payments to 835 clinicians in Hematology in 2025. See who received the most
Source: CMS Open Payments, program year 2025. A payment is not evidence of wrongdoing.
Research in this field
U.S. researchers published 21,784 articles and reviews in hematology in 2024–2026.
Journals with the most U.S. papers
- Clinical Lymphoma Myeloma & Leukemia Elsevier BV 1,441
- Transplantation and Cellular Therapy Elsevier BV 1,169
- Blood Advances Elsevier BV 684
- Blood Elsevier BV 634
- Cureus Cureus, Inc. 488
- Journal of Clinical Oncology Lippincott Williams & Wilkins 462
- Transfusion Wiley 422
- Haematologica Ferrata Storti Foundation 422
- Leukemia Springer Nature 325
- American Journal of Hematology Wiley 312
Most-cited recent papers
- Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management (opens in a new tab) American Journal of Hematology, 2024 · cited 588 times · free to read
- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults (opens in a new tab) New England Journal of Medicine, 2024 · cited 294 times · free to read
- Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations (opens in a new tab) Blood, 2024 · cited 286 times · free to read
- Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) (opens in a new tab) Journal of Clinical Oncology, 2024 · cited 272 times · free to read
- Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management (opens in a new tab) American Journal of Hematology, 2025 · cited 259 times · free to read
- Long‐term follow‐up of VIALE‐A : Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia (opens in a new tab) American Journal of Hematology, 2024 · cited 259 times · free to read
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children (opens in a new tab) New England Journal of Medicine, 2024 · cited 253 times · free to read
- EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease (opens in a new tab) Annals of the Rheumatic Diseases, 2024 · cited 250 times · free to read
From OpenAlex, an open index of research papers. Papers with at least one author at a U.S. institution, classified by subject; the subject covers the whole field, so related specialties share these lists. Citation counts change daily.
Sources: CMS NPPES (counts, sex, credentials), Medicare Care Compare (schools, graduation years, hospitals, telehealth), CMS Medicare Physician & Other Practitioners (2023) and Part D Prescribers (2024), CMS Open Payments (2025), ACGME program requirements (training length), OpenAlex (research), U.S. Census Bureau ACS 2020–2024 (population).